SUTTER MARTIN P 4
4 · Bioventus Inc. · Filed Jun 4, 2026
Research Summary
AI-generated summary of this filing
Bioventus (BVS) 10% Owner Martin Sutter Exercises Derivatives, Receives RSUs
What Happened
Martin P. Sutter, reported as a 10% owner and a manager of the general partner that controls certain Bioventus holdings, had 32,282 restricted stock units (RSUs) vest and convert into 32,282 shares on June 2, 2026 (exercise/conversion of a derivative; $0.00 per share). The Form 4 also shows a corresponding derivative "disposed" entry for the same 32,282 units on June 2, which reflects the settlement/conversion of the RSUs rather than an open-market sale. On June 3, 2026 he was granted 25,146 additional RSUs (award) at $0.00 per unit. No cash was paid or received in these transactions.
Key Details
- Transaction dates and prices: June 2, 2026 — 32,282 RSUs vested/converted into common shares at $0.00; June 3, 2026 — grant of 25,146 RSUs at $0.00.
- Total immediate shares received: 32,282 common shares; new contingent award: 25,146 RSUs. Cash exchanged: $0.00.
- Shares owned after transaction: the filing does not state Sutter’s individual share total. Footnote F1 shows funds managed by the group hold 12,096,702 and 924,622 Class A shares; the Managers disclaim beneficial ownership except for pecuniary interest.
- Footnotes: F2 = each RSU converts to one share; F3 = RSUs that vested did so on June 2, 2026; F4 = new RSUs vest the earlier of the first post‑grant annual meeting or one year, subject to continued board service.
- Timeliness: Form filed June 4, 2026 for transactions on June 2–3 — appears to be filed within the usual Form 4 timing (no late filing indicated).
- Transaction codes: M = exercise/conversion of derivative; A = award/grant.
Context
These entries are typical compensatory events for board members or managers (vesting and new RSU grants) and are not open-market purchases or sales that would signal a directional trade. As a reported 10% owner through managed funds, Sutter’s activity primarily reflects RSU settlement and a new award tied to board service; it should be viewed as routine insider compensation rather than a market-driven buy or sell.
Insider Transaction Report
- Exercise/Conversion
Class A Common Stock
2026-06-02+32,282→ 117,523 total - Exercise/Conversion
Restricted Stock Units
[F2][F3]2026-06-02−32,282→ 0 total→ Class A Common Stock (32,282 underlying) - Award
Restricted Stock Units
[F2][F4]2026-06-03+25,146→ 25,146 total→ Class A Common Stock (25,146 underlying)
- 13,021,324(indirect: See Footnote)
Class A Common Stock
[F1]
Footnotes (4)
- [F1]Includes 12,096,702 shares of Class A Common Stock held by EW Healthcare Partners Acquisition Fund, L.P. ("Essex Stockholder") and 924,622 shares of Class A Common Stock held by White Pine Medical, LLC ("White Pine"). EW Healthcare Partners Acquisition Fund UGP, LLC ("General Partner") is the general partner of EW Healthcare Partners Acquisition Fund GP, L.P., which is the general partner of Essex Stockholder, which is the managing member of White Pine. Messrs. Sutter, Vainio, Eastman, and Barry (collectively, the "Managers") are the managers of the General Partner. The Managers disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein.
- [F2]Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock.
- [F3]The RSUs vested on June 2, 2026.
- [F4]The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date.